Last reviewed · How we verify
A Multicenter, Nonrandomized, Open-Label Phase 1 Safety Study of HspE7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects
The purpose of this study is to determine the safety and tolerability of HspE7 and Poly-ICLC when given together
Details
| Lead sponsor | Nventa Biopharmaceuticals Corporation |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 24 |
| Start date | 2007-05 |
| Completion | 2008-06 |
Conditions
- Cervical Intraepithelial Neoplasia
Interventions
- HspE7 and Poly-ICLC
Primary outcomes
- Safety of HspE7 and Poly-ICLC administered concomitantly for Cervical Intraepithelial Neoplasia — 4 Weeks after the last of 3 Injections
Countries
United States